

FDA Doubles Down in Its Updated Biologics Naming Guidance

March 19, 2019

ATTORNEYS

Landmon, Chad

PRACTICE AREAS

Biotechnology

FDA

Chad Landmon

The Center for Biosimilars

The Center for Biosimilars published, "FDA Doubles Down in Its Updated Biologics Naming Guidance," an article co-authored by Axinn partner Chad Landmon.

[Click here to access the article.](#)